2	
3	Diagnostic test accuracy of artificial intelligence in screening for referable diabetic
4	retinopathy in real-world settings: A systematic review and meta-analysis
5	
6	
7	Holijah Uy <sup>1*</sup> , Christopher Fielding <sup>2</sup> , Ameer Hohlfeld <sup>3</sup> , Eleanor Ochodo <sup>4,5</sup> ,
8	Abraham Opare <sup>1</sup> , Elton Mukonda <sup>2</sup> , Deon Minnies <sup>1</sup> ¶, Mark E Engel <sup>3,6*¶</sup>
9	
10	
11	
12 13	<sup>1</sup> Community Eye Health Institute, Faculty of Health Sciences, University of Cape Town, South Africa
14 15	<sup>2</sup> Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of Cape Town, South Africa
16	<sup>3</sup> South African Medical Research Council, South Africa
17	<sup>4</sup> Centre for Global Health Research, Kenya Medical Research Institute, Kenya
18	<sup>5</sup> Department of Global Health, Stellenbosch University, South Africa
19	<sup>6</sup> Department of Medicine, University of Cape Town, South Africa
20	
21	* Corresponding authors
22	E-mail: mark.engel@uct.ac.za (MEE); uyxhol001@myuct.ac.za (HU)
23	
24	<sup>¶</sup> DM and MEE are Joint Senior Authors

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 25 Abstract

26 Studies on artificial intelligence (AI) in screening for diabetic retinopathy (DR) have shown promising 27 results in addressing the mismatch between the capacity to implement DR screening and the increasing DR incidence; however, most of these studies were done retrospectively. This review sought to evaluate 28 29 the diagnostic test accuracy (DTA) of AI in screening for referable diabetic retinopathy (RDR) in realworld settings. We searched CENTRAL, PubMed, CINAHL, Scopus, and Web of Science on 9 30 February 2023. We included prospective DTA studies assessing AI against trained human graders 31 32 (HGs) in screening for RDR in patients living with diabetes. synthesis Two reviewers independently 33 extracted data and assessed methodological quality against QUADAS-2 criteria. We used the hierarchical summary receiver operating characteristics (HSROC) model to pool estimates of sensitivity 34 and specificity and, forest plots and SROC plots to visually examine heterogeneity in accuracy 35 36 estimates. Finally, we conducted sensitivity analyses to explore the effects of studies deemed to possibly 37 affect the quality of the studies. We included 15 studies (17 datasets: 10 patient-level analysis (N=45,785), and 7 eye-level analysis (N=15,390). Meta-analyses revealed a pooled sensitivity of 38 95.33%(95% CI: 90.60-100%) and specificity of 92.01%(95% CI: 87.61-96.42%) for patient-level 39 40 analysis; for the eve-level analysis, pooled sensitivity was 91.24% (95% CI: 79.15-100%) and specificity, 93.90% (95% CI: 90.63-97.16%). Subgroup analyses did not provide variations in the 41 diagnostic accuracy of country classification and DR classification criteria; however, a moderate 42 increase was observed in diagnostic accuracy at the primary-level and, a minimal decrease in the 43 44 tertiary-level healthcare settings. Sensitivity analyses did not show any variations in studies that 45 included diabetic macular edema in the RDR definition, nor in studies with  $\geq$ 3 HGs. This review 46 provides evidence, for the first time from prospective studies, for the effectiveness of AI in screening for RDR, in real-world settings. 47

48

# 50 Introduction

Diabetic retinopathy (DR) is the most common and specific complication of diabetes mellitus in the working age group [1]. In 2020, the number of adults with DR was estimated to be 103.12 million, which is expected to be 129.84 million by 2030 and 160.50 million by 2045 [1]. Along with an increasing incidence of DR, the number of people with vision impairment and blindness also increases. Without early intervention, the incidence of blindness due to DR will continue to rise as the number of people getting diabetes increases. Thus, DR has become a global public health concern, compelling researchers and health practitioners to continuously develop strategies to prevent and treat DR.

Diabetic retinopathy can be asymptomatic for years, even at advanced stages [2]. Thus, early-stage 58 59 detection of DR is crucial to provide timely treatment and management. For that reason, DR screening 60 programmes are being implemented in public health settings through population-based or opportunistic 61 screening. Diabetic retinopathy screening aims to distinguish between patients who need a referral, 62 termed referable DR (RDR), for ophthalmological intervention from those who can continue annual 63 routine eye care services [3]. Referable DR can be classified as moderate nonproliferative DR (NPDR) 64 or worse and/or diabetic macular edema (DME). Those with RDR must be referred within three months to one year, depending on the resource settings [4]. 65

66 Currently, local and international programmes combatting DR are facing a significant crisis due to the 67 increasing prevalence of diabetes. This influx has outpaced the development of healthcare services and 68 screening programmes for preventing DR [5]. According to a systematic review by Piyasena et al. [6], 69 aside from the high cost of services and lack of infrastructure for retinal imaging and training 70 programmes, one of the major barriers to DR screening is the lack of skilled human resources, especially 71 in the lower- and middle-income countries.

Artificial intelligence has shown to be a promising solution to these challenges by functioning in an autonomous mode. Through deep learning algorithms, AI can be used to detect the presence and severity of DR in real-time. However, it is crucial that these tools should have high diagnostic accuracy and good performance before being implemented in various healthcare settings. The UK National Institute for Clinical Excellence (NICE) Guidelines stated that DR screening programmes should use screening

tools with a sensitivity of  $\ge 80\%$ , specificity of  $\ge 95\%$ , and a technical failure rate of  $\le 5\%$  [7]. Meanwhile, the St Vicent Declaration of 2005 suggested that systematic DR screening programmes should aim for a sensitivity of  $\ge 80\%$  and a specificity of  $\ge 90\%$  with an acceptable coverage of  $\ge 80\%$ [8].

81 In recent years, retrospective validation studies have shown AI to have high diagnostic accuracy in detecting DR; that is, AI is equally good or even better than human graders (HGs). Studies done in real-82 world settings using prospective data collection have also demonstrated robust performance [9]; 83 84 however, these studies are fewer than those done in a retrospective manner, and the true utility of AI systems in DR screening will only be better understood through prospective studies, as performance is 85 86 likely to be affected when dealing with real-world data that is different from the data used for algorithm 87 training [10, 11]. Moreover, prospective studies, with pre-established protocols, allow them to be more 88 robust and generalisable, and exhibit the true impact on system usability in real-world settings.

Therefore, we conducted a systematic review and meta-analysis of studies with prospective data collection in assessing the diagnostic accuracy of AI compared with trained HGs in screening for RDR in real-world settings. The findings of this review may offer evidence-based recommendations for integrating AI solutions to screen for RDR, especially in resource-challenged environments.

93

# 94 Methods

## 95 Reporting, protocol, and registration

We drafted this review in accordance with the Preferred Reporting Items for Systematic Review and
Meta-analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) guidelines [12]. The study
protocol was registered with the International Prospective Register of Systematic Reviews
(PROSPERO) under CRD42023392297. An ethics waiver was granted by the University of Cape Town
Human Research Ethics Committee.

# 101 Databases and search strategies

We searched the following electronic databases: Cochrane Central Register of Controlled Trials
(CENTRAL), Medical Literature Analysis and Retrieval System Online (MEDLINE) via PubMed,
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, and Web of Science (S1
Table). We also hand-searched the reference lists of relevant primary studies, systematic reviews, and
the following journals: British Journal of Ophthalmology, American Journal of Ophthalmology,
Ophthalmology and Retina, JAMA Ophthalmology, and Investigative Ophthalmology and Visual
Science.

109

# 110 Eligibility criteria

### 111 **Type of studies**

112 We included randomised control trials (RCT) and observational analytical studies evaluating the DTA

of AI in DR screening. We excluded studies based on retrospective validation of existing images (i.e.,

medical records, available data sets). We excluded review articles, editorials, case series, case reports,and qualitative studies.

### \_\_\_\_\_

116 **Type of participants** 

We included participants with clinically diagnosed type 1 or type 2 diabetes with unknown DR status, regardless of age, sex, race/ethnicity, and geographical location. We excluded studies that enrolled participants with unconfirmed diabetes to avoid misclassifying participants, which may result in biased estimates of the association between diabetes and diabetic retinopathy.

### 121 Setting

We only included studies conducted in real-world settings, thus excluding those done for theoreticalalgorithm training and validation alone.

### 124 Index test

We included interventions using AI for prospective screening of fundus images that could detect RDRor its equivalent.

### 127 **Reference standard**

128 The reference standard was manual grading for DR by trained HGs who analysed the same fundus

images read by the AI. We excluded reference standards that did not use the same DR classification

130 criteria used by the AI during its software training to grade DR.

### 131 Target condition

We included studies that screened for RDR as defined by the authors of the primary studies. We included studies with RDR equivalence, i.e. more than mild DR, clinically significant DR, etc. We did not include patients or eyes with no RDR, and ungradable or inconclusive fundus images in the pooling of diagnostic accuracy outcomes. Including ungradable or inconclusive images may result in inaccuracy in assessing the AI system's performance, making it challenging to draw meaningful conclusions.

### 137 Outcomes

We included studies reporting on, or containing the data necessary to extract information on the
proportions of true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN).
Efforts were made to contact corresponding authors to retrieve data which were unclear or unavailable
in the paper or supplementary materials.

### 142 **Report characteristics**

143 We had no restrictions on the publication year and language. Study protocols were excluded.

- 144
- 145
- 146
- 147

# 148 Study selection

149 We used Rayyan software to manage the retrieved studies. Review authors (HU, CF) independently 150 screened the titles and abstracts and classified them as (a) included, (b) maybe, and (c) excluded. Full-151 text articles of those 'included' and 'maybe' were obtained and independently assessed by the same 152 authors against the eligibility criteria. Studies were then classified as (a) included, (b) excluded, and (c) awaiting authors' responses. Any disagreements were resolved between the two reviewers or by 153 154 consulting a third review author (AH). We emailed the corresponding authors of studies included as 155 'awaiting authors' responses' at least three times with intervals of at least two weeks. If there were no 156 responses from the authors, studies were classified under 'no author's response'.

# 157 Data extraction and management

We developed a data extraction form and divided it into two parts: (a) Study characteristics (relating to study designs, AI, and reference standards) and (b) Study outcomes: TP, FP, FN, TN. Two review authors extracted the study characteristics and study outcomes.

# 161 **Risk of bias and acceptability**

The risk of bias and applicability on the (a) patient selection, (b) index test, (c) reference standard, and (d) flow and timing of the included studies were independently assessed by two review authors (HU, CF) using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool [13]. We tailored, piloted, and refined our QUADAS-2 tool based on our review. Any disagreements were resolved between the two authors or by consulting a third review author (ME).

## 167 Data synthesis and analysis

## 168 Quantitative data analysis and synthesis

We calculated each included study's sensitivity and specificity. We initially planned to analyse data only at the patient level; however, some studies reported only diagnostic accuracy on eye level (or image level), and some patient-level data cannot be extracted. Therefore, we considered looking into both of these levels for analysis. Heterogeneity was explored using visual inspection of forest plots and hierarchical summary receiver operating characteristics (HSROC) plots. All analyses performed and
plots generated were done using Review Manager (RevMan) 5.4 and SAS® Studio.

### 175 Subgroup analysis

We performed subgroup analyses on the following covariates identified a priori: level of economic development (World Bank country classification), level of the healthcare setting, and DR classification criteria. We did not include the modes of AI as previously planned since all AI modes of the included studies were automated.

### **180** Sensitivity analysis

We initially planned to explore the effect of excluding studies with a high risk of bias. However, after 181 excluding studies with a high risk of bias, all studies were left with an unclear risk. Nevertheless, we 182 183 performed sensitivity analyses to investigate the exclusion of studies that did not include DME in the RDR definition; although we have stated that the definition of RDR will be according to how the authors 184 185 of the primary studies defined it, many references still included DME as part of RDR definition, and 186 the International Council of Ophthalmology (ICO) guidelines states that patients with DME should be 187 referred. We also investigated the exclusion of studies with  $\leq 2$  HGs as the ground truth for reference 188 standard because this might incur bias if intergrader disagreements arise without having a third HG to 189 arbitrate. According to Cardoso et al., ground truth means "data and/or method related to more 190 consensus or reliable values/aspects that can be used as references" [14]. In our review, it refers to the 191 final grading or assessment of fundus images by all HGs, which serves as the reference standard or the 192 most reliable evaluation of the presence and severity of DR.

193

# 194 **Results**

# 195 **Results of the Search**

We were able to identify a total of 3899 articles through searching of various databases. After deduplication, 2742 studies were screened by title/abstract, of which 2654 were excluded. The remaining 88 studies were screened for full-text assessment against the review's eligibility criteria. Of

- these, 70 studies were excluded, three were classified under 'no author's response', and finally, 15 wereincluded for the quantitative synthesis (Fig 1).
- Fig 1. PRISMA flow diagram of the study search and selection.
- 202

### 203 Included studies

204 Please see Tables 1a and 1b for the characteristics of included studies. Fifteen studies comprising 17 datasets were deemed eligible for this review, of which ten measured diagnostic accuracies at the patient 205 206 level (45 785 patients) and seven at the eve level (15 390 eyes). We deemed all studies to be crosssectional with prospective data collection; however, in our table of included studies, we presented the 207 study designs according to how they were reported. Seven studies were done in China, five in India, 208 209 and three in Australia. Seven studies were done at tertiary-level healthcare settings, six were done at the primary level, while the remaining two were done at both levels; no studies were done at the 210 secondary level. For the target condition (RDR), six studies defined it as moderate NPDR or worse 211 and/or DME, and nine did not include DME as part of the definition. Thirteen studies used ICDR or its 212 213 equivalence as DR classification criteria, and two used the NHS DES criteria. For the reference standard, 12 studies have  $\geq$ 3 HGs as the ground truth, and three studies have at most two HGs. Four 214 215 studies developed their own AI models, and 11 used commercially available models. All studies used 216 Inception with varying versions as their architecture. All AI software in the studies were fine-tuned with 217 training data sets containing 25 297 to 207 228 fundus images. All studies used nonmydriatic cameras 218 to capture fundus images, of which three still performed mydriasis on their patients using tropicamide 219 eye drops, and one did mydriasis on a conditional protocol. Eight studies captured only one fundus field 220 per eye (mostly macula-centred), and seven studies captured more than one fundus field. All studies 221 used a fundus camera with a narrow field of vision (45°-50°).

	•	St	tudy Settings	8	Pat	ient Charac	teristics	Target Condi	tion	Reference Standard/ Ground Truth (№)		
Study	Study Design <sup>a</sup>	Country (WBC)	Setting (№)	Healthcare Setting	Age, mean (SD), years	Type of Diabetes	Sample Size <sup>b</sup> (Patients/Eyes)	Definition of RDR/ Equivalence	Criteria Used	If without disagreement	If with disagreement	
Dong 2022 [15]	Cross-sectional	China (U-MIC)	Community healthcare centres (3)	Primary	52.09 (±11.51)	T1D, T2D	Eyes: 848	Moderate NPDR or worse (DME not included)	ICDR	Gradings made by the ophthalmologists (2)	Gradings made by a senior retinal specialist (1)	
Gulshan 2019 [16]	Prospective observational	India (L-MIC)	Eye care centre (Aravind Eye Hospital only)	Tertiary	56.60 (±9.00)	T1D, T2D	Eyes: 1905 °	Moderate NPDR or worse (DME not included)	ICDR	Gradings made by retinal specialists (3)	any disagreements discussed until a full consensus was achieved	
Hao 2022 [17]	Prospective clinical trial	China (U-MIC)	Local community hospital	Primary	63.03 (±8.72)	T1D, T2D	Eyes: 6854	Moderate NPDR or worse (DME not included)	ICDR	Gradings made by the ophthalmologists (2)	Gradings made by a senior ophthalmologist (1)	
He 2020 [18]	Cross-sectional <sup>d</sup>	China (U-MIC)	Community hospital clinic	Primary	68.46 (±7.20)	T1D, T2D	Patients: 889	Moderate NPDR or worse and/or DME	ICDR	Gradings made by the retina specialists (2)	Gradings made by a third retinal specialist (1)	
Jain 2021 [19]	Cross-sectional	India (L-MIC)	Municipal dispensaries (47)	Primary	54.90 (±10.43)	T1D, T2D	Patients: 1370 Eyes: 2626	Moderate NPDR or worse (DME not included)	ICDR	Gradings made by the retina specialists (2)	Gradings made by a third retinal specialist (1)	
Kanagas- ingam 2018 [20]	Cross-sectional <sup>d</sup>	Australia (HIC)	Primary care clinic	Primary	55.00 (±17.00)	T1D, T2D	Patients: 193	Moderate NPDR or worse (DME not included)	ICDR	Grading made by an oph	halmologist (1) alone	
Keel 2018 [21]	Prospective observational	Australia (HIC)	Urban endocrinology outpatient clinics (2)	Tertiary	44.26 (±16.56)	T1D, T2D	Patients: 93	Moderate NPDR or worse and/or DME	NHS DES	Grading made by the cen centre	tralised retinal grading	
Li 2021 [22]	Prospective observational	China (U-MIC)	General hospital	Tertiary	50.00 (±12.00)	T1D, T2D	Eyes: 1674 °	Moderate NPDR or worse (DME not included)	ICDR	Grading made by a retina	specialist (1) alone	
Natarajan 2019 [23]	Prospective, cross-sectional	India (L-MIC)	Municipal dispensaries	Primary	53.10 (±10.30)	T1D, T2D	Patients: 214 Eyes: 394	Moderate NPDR and worse, with or without DME	ICDR	Grading made by the ophthalmology resident (1) and retina specialist (1)	Gradings made by the same retina specialist	
Rajalakshmi 2018 [24]	Cross-sectional <sup>d</sup>	India (L-MIC)	Diabetes centre	Tertiary	NR	T2D	Patients: 296	Moderate NPDR or worse and/or DME	ICDR	Gradings made by the retina specialists (2)	Gradings made by a third retinal specialist (1)	
Scheetz 2021 [25]	Prospective observational	Australia (HIC)	Endocrinology outpatient clinics (2) and Aboriginal medical services clinics (3)	Primary and Tertiary	54.25 (±20.16) °	T1D, T2D	Patients: 203	Moderate NPDR or worse and/or DME	NHS DES	Gradings made by NHS-certified graders (2)	Gradings made by retinal specialists (2)	
Sosale 2020 [26]	Prospective, cross-sectional	India (L-MIC)	Diabetes centre	Tertiary	NR	T1D, T2D	Patients: 900	Moderate NPDR or worse and/or DME	ICDR	The majority diagnosis o	f the retina specialists (5)	
Yang 2022 [27]	Observational, prospective, multicentre, gold standard-controlled	China (U-MIC)	Hospital and ophthalmic centres (3)	Tertiary	60.44 (±10.19) °	T1D, T2D	Patients: 962	Stage II or worse DR (DME not included)	COS f	Gradings made by ZIRC graders (2)	Gradings made by a third senior ZIRC grader (1)	
Zhang 2020 [28]	Prospective observational	China (U-MIC)	Diabetes centres (155)	Primary and Tertiary	54.29 (±11.60)	T1D, T2D	Patients: 40 665	Moderate NPDR or worse (DME not included)	ICDR	Gradings made by the ophthalmologists (2)	Gradings made by a senior ophthalmologist (1)	
Zhang 2022 [29]	Prospective, multicentre, self- controlled clinical trial	China (U-MIC)	Hospitals (3)	Tertiary	56.52 (±11.13)	T1D, T2D	Eyes: 1089	Moderate NPD or worse (DME not included)	ICDR	Gradings made by the ophthalmologists (3)	Gradings made by the principal investigator ophthalmologist (1)	

### Table 1a. Key characteristics of the study design, population, target condition, and reference standard of included studies.

<sup>*a*</sup> Study design according to study authors; <sup>b</sup> Sample included in the diagnostic accuracy analysis excluding ungradable images; <sup>c</sup> Samples were reported in image level, but the study captured one image per eye, so considered as eye-level; <sup>d</sup> Study design not reported, thus deemed by review authors as cross-sectional based on the journals; <sup>e</sup> Mean was estimated from median using recommendations by Hong Kong Baptist University, Department of Mathematics [30]; <sup>f</sup> Criteria was matched to the equivalent definition of RDR based on the ICDR classification.

COS, Chinese Ophthalmic Society; CSME, clinically significant macular edema; DME, diabetic macular edema; DR, diabetic retinopathy; ETDRS, Early Treatment Diabetic Retinopathy Study; HIC, high-income country; ICDR, International Clinical Diabetic Retinopathy; L-MIC, lower middle-income country; NHS DES, National Health Service Diabetic Eye Screening; NPDR, nonproliferative diabetic retinopathy; NR, not reported; RDR, referable diabetic retinopathy; SD, standard deviation; T1D, Type 1 diabetes; T2D, Type 2 diabetes; U-MIC, upper middle-income country; WBC, World Bank classification; ZIRC, Zhongshan Image Reading Centre.

### Table 1b. Key characteristics of the index tests of included studies.

		Artificial Intell	igence Devel	opment			Fundus Camera Used			
Study	AI Model	Architecture	Neural Network	Pre- trained	Fine- tuned	Training Dataset (№ of fundus images)	Mydriatic or Nonmydriatic Camera	№ of Fundus Fields	Field of Vision	
Dong 2022 [15]	CARE, Shanghai EagleVision Medical Technology Co., Ltd (Airdoc)	Inception- ResNet-v2	CNN	Yes	Yes	Clinical settings datasets (207 228)	Nonmydriatic	1 field (macula-centred)	50°	
Gulshan 2019 [16]	Own AI model	Inception-v3	CNN	Yes	Yes	EyePACS and hospital datasets (128 175)	Nonmydriatic	1 field (macula-centred)	45°	
Hao 2022 [17]	EyeWisdom (Visionary Intelligence Ltd., Beijing, China)	Inception-v3	CNN	Yes	Yes	EyePACS and hospital datasets (25 297)	Nonmydriatic	2 fields (macula- and optic disc- centred)	45°	
He 2020 [18]	Airdoc, Beijing, China	Inception-v4	CNN	Yes	Yes	Unspecified dataset (number of fundus images NR)	Nonmydriatic	2 fields (macula- and optic disc- centred)	45°	
Jain 2021 [19]	Medios AI (Remidio)	Inception-v3 and MobileNet	CNN	Yes	Yes	EyePACS, hospital and screening camps datasets (52 894)	Nonmydriatic, but patients underwent mydriasis (1% tropicamide)	3 fields (posterior pole including macula & disc, nasal, and temporal)	45°	
Kanagas- ingam 2018 [20]	Own AI model	Inception-v3 (customised)	CNN	Yes	Yes	DiaRetDB1, EyePACS, and Tele-eye care DR database (30 000)	Nonmydriatic	1 field (macula-centred)	45°	
Keel 2018 [21]	Own AI model	Inception-v3	CNN	NR	Yes	LabelMe dataset (58 790)	Nonmydriatic	1 field (central nasal)	45°	
Li 2021 [22]	VoxelCloud, China	Inception- ResNet-v2	CNN	Yes	Yes	EyePACS and hospital datasets (141 184)	Nonmydriatic	1 field (macula-centred)	45°	
Natarajan 2019 [23]	Medios AI (Remidio)	Inception-v3 and MobileNet	CNN	Yes	Yes	EyePACS, hospital and screening camps datasets (52 894)	Nonmydriatic, but patients underwent mydriasis (1% tropicamide)	3 fields (posterior pole including macula & disc, nasal, and temporal)	45°	
Rajalakshmi 2018 [24]	EyeArt v2.1	NR	DNN	Yes	Yes	EyePACS (number of fundus images NR)	Nonmydriatic, but patients underwent mydriasis (tropicamide)	4 fields (macula-centred, optic disc-centred, superior-temporal, and inferior-temporal quadrants of the retina)	45°	
Scheetz 2021 [25]	Own AI model	Inception-v3	CNN	NR	Yes	LabelMe dataset (71 043)	Nonmydriatic	1 field (macula-centred)	45°	
Sosale 2020 [26]	Medios AI (Remidio)	Inception-v3 and MobileNet	CNN	Yes	Yes	EyePACS, hospital and screening camps datasets (52 894)	Nonmydriatic	2 fields (macula- and optic disc- centred)	45°	
Yang 2022 [27]	AIDRScreening v1.0 (Shenzhen SiBright CO. Ltd., China)	NR	CNN	NR	Yes	Eye institute, endocrinology department, and eye examination centre datasets (73 849)	Both; if pupil diameter was >4 mm, fundus photography was performed without mydriasis; otherwise, mydriasis was required	2 fields (macula- and optic disc- centred)	45°	
Zhang 2020 [28]	VoxelCloud Retina, China	Inception- ResNet-v2	CNN	Yes	Yes	EyePACS and hospital datasets (144 810)	Nonmydriatic	1 field (macula-centred)	4 <mark>5°</mark>	
Zhang 2022 [29]	EyeWisdom v1 (Visionary Intelligence Ltd., Beijing, China)	Inception-v3 and ResNet-34	CNN	Yes	Yes	Hospital and ILSVRC subset of ImageNet datasets (40 693)	Nonmydriatic	1 field (posterior pole containing macula and optic disc)	4 <u>5</u> °	

CARE, Comprehensive AI Retinal Expert; CNN, convolutional neural network; DNN, deep neural network; ILSVRC, ImageNet Large Scale Visual Recognition Challenge; NR, not reported

### 223 Excluded studies

- From the 88 full-text articles assessed for eligibility, we excluded 70 studies and classified three
- studies under 'no author's response'.

# 226 Methodological quality of included studies

- A summary of methodological quality assessment is presented in Figs 2 and 3.
- 228 Fig 2. Risk of bias and applicability concerns summary: Review authors' judgments about each
- domain for each included study using the QUADAS-2 tool.
- 230 Fig 3. Risk of bias and applicability concerns graph: Review authors' judgments about each
- 231 domain presented as percentages across included studies using the QUADAS-2 tool.
- 232

### 233 Patient selection

234 In the patient selection domain, 12 of the 15 studies were deemed to have an unclear risk of bias in the sampling method. Most of the studies did not specify how patients were enrolled except for three studies 235 (1 consecutive, 1 random, and 1 convenience sampling method). Two studies were not able to avoid 236 inappropriate exclusions since one study excluded patients with macular edema, and the other study 237 238 excluded those who were treated with ocular injections for DME or proliferative disease; of which these conditions are part of the definition of RDR, deeming these studies with a high risk of bias and high 239 concern on applicability. For applicability on patient selection, 13 out of 15 studies have a low concern 240 on applicability. 241

242

### 243 Index test

In the domain of index tests, we added two signalling questions deemed necessary for index tests using AI, one of which is the quality of images fed into the AI system. This is vital since images with insufficient quality (i.e., overexposed, out-of-focus, etc.) may be deemed ungradable or be misclassified. Another signalling question added was on the conflict of interest. With the advent of AI in healthcare, several AI software packages are currently being developed; thus, if study authors wereaffiliated with or funded by the software company in any way, studies may incur a high risk of bias.

In this domain, the main quality issue was the signalling question of whether a diagnostic threshold was prespecified or not. Only three studies reported on prespecified thresholds, with the remaining 12 studies thus considered to have an unclear risk of bias. Six studies have conflicts of interest, thus deeming them high risk. All studies have low applicability concerns for the index test.

254

### 255 **Reference standard**

In the reference standard domain, three out of 15 studies were evaluated as having a high risk of bias because there were only two HGs to grade the fundus images. This may incur bias since grading images can be very subjective, and there is no one to arbitrate when a disagreement arises. Five studies have an unclear risk of bias because they did not explicitly state whether the HGs were blinded to the results of the AI grading results. All studies have low applicability concerns.

261

### 262 Flow and timing

In the domain of flow and timing, one study was considered to be of a high risk of bias because it was not able to explain the discrepancies in patients enrolled and analysed clearly. This domain is not assessed regarding applicability concerns, as stated in the QUADAS-2 tool.

266

# 267 Findings

We evaluated the accuracy of AI in screening for RDR in real-world settings according to patient-level and eye-level analysis compared with HGs. The patient-level analysis was considered the main metaanalysis since it is the number of patients with RDR who will be referred to ophthalmologists for further assessment. Out of the 15 studies reviewed, eight presented diagnostic accuracy based solely on patient-

- 272 level information, five showed diagnostic accuracy based solely on eye-level information, and two
- showed diagnostic accuracy based on both patient-level and eye-level information.
- 274 The HSROC model by Rutter and Gatsonis was used for the meta-analysis as this model accounts for
- the variations in the test thresholds among the AI models [31]. We performed subgroup analysis and
- investigated for heterogeneity using the World Bank country classification, level of the healthcare
- 277 setting, and DR classification criteria.
- 278 We performed sensitivity analyses to explore the effect of excluding (1) studies that did not include
- 279 DME in the RDR definition and (2) studies with a total number of  $\leq 2$  HGs as the ground truth. Table
- 280 2 shows the detailed overall patient-level and eye-level meta-analysis.

281

 Table 2. Overall patient-level and eye-level meta-analysis of the accuracy of AI in detecting RDR compared with trained HGs.

Overall Meta-analysis	№ of Studies	№ of Samples	Sensitivity (95% CI)	Specificity (95% CI)
Patient-level	10	45 785 patients	95.33% (90.60-100)	92.01% (87.61-96.42)
Eye-level	7	15 390 eyes	91.24% (79.15-100)	93.90% (90.63-97.16)

Data calculated using SAS® Studio.

CI, Confidence Interval; HG, human grader.

### 282

### 283 Patient-level analysis

Ten evaluations of AI for RDR screening were performed with data from ten studies and a total of 45

285 785 patients. The forest plot (Fig 4) shows minimal variation in the accuracy estimates. The HSROC

plot (Fig 5) reveals good test accuracy since most study points lie in the upper left corner of the plot.

287 Meta-analytical sensitivity and specificity of data at mixed thresholds were 95.33% (95% CI 90.60-

288 100) and 92.01% (95% CI 87.61-96.42), respectively.

- Fig 4. Coupled forest plot of included studies for patient-level analysis.
- Fig 5. HSROC plot of sensitivity vs specificity of AI for detecting RDR on patient-level analysis.
- 292

# 293 Eye-level analysis

- A total of seven evaluations of AI for RDR screening were performed with data from seven studies and
- a total of 15 390 eyes. We only included the Aravind data from the Gulshan 2019 study because data
- 296 from Sankara differed from our eligibility criteria.
- 297 The forest plot (Fig 6) shows moderate variation in the estimates of sensitivity and minimal variation
- in specificity. The HSROC plot (Fig 7) reveals good test accuracy since most study points lie in the
- 299 upper left corner of the plot. Meta-analytical sensitivity and specificity of data at mixed thresholds were

300 91.24% (95% CI 79.15-100) and 93.90% (95% CI 90.63-97.16), respectively.

- 301
- **302** Fig 6. Coupled forest plot of included studies for eye-level analysis.

**303** Fig 7. HSROC plot of sensitivity vs specificity of AI for detecting RDR on eye-level analysis.

304

### 305 **Exploring heterogeneity**

We performed subgroup analyses to explore potential sources of heterogeneity only on the main
analysis (patient level), consisting of ten studies, since the data for the subgroups were more complete.
A detailed result of subgroup analyses investigating potential sources of study-level heterogeneity is
shown in Table 3.

- 310
- 311
- 312
- 313
- 314
- 315
- 316

Analysis		№ of Studies	№ of Participants	Sensitivity (95% CI)	Specificity (95% CI)
<b>Overall Meta-analy</b>	ysis				
Patient-level		10	45 785	95.33% (90.60-100)	92.01% (87.61-96.42)
Subgroup Analyses	8				
World Bank	LMIC	7	45 296	95.38% (90.38-100)	92.21% (87.19-97.23)
Classification	HIC	3	489	95.61% (89.44-100)	90.82% (87.76-93.87)
Level of Health-	Primary	4	2666	99.35% (96.85-100)	93.72% (88.83-98.61)
care Setting <sup>a</sup>	Tertiary	4	2251	94.71% (89.00-100)	90.88% (83.22-98.53)
DR Classification	ICDR	8	45 489	95.44% (90.70-100)	92.21% (87.80-96.62)
Criteria	NHS DES	2	296	95.49% (89.19-100)	89.85% (84.93-94.77)

 Table 3. Subgroup analyses for the accuracy of AI in detecting RDR compared with trained HGs on patient-level analysis.

<sup>a</sup> No studies reported on secondary healthcare settings, thus not included in this table. Data calculated using SAS<sup>®</sup> Studio.

**CI**, Confidence Interval; **HG**, human grader; **HIC**, high-income country; **ICDR**, International Clinical Diabetic Retinopathy; **LMIC**, lower- and middle-income country; **NHS DES**, National Health Service Diabetic Eye Screening; **RDR**, referable diabetic retinopathy.

### 317

### 318 Level of economic development

319 We classified the level of economic development of the countries included in our study using

- 320 classification by the World Bank Group [32]. Of the ten studies included, three were conducted in HICs,
- 321 and seven were conducted in LMICs. Australia was classified as a high-income country (HIC), and
- 322 China and India, as lower- and middle-income country (LMIC). The sensitivity and specificity of AI in
- the real-world screening for RDR in LMICs were 95.38% and 92.21%, respectively, and in HIC, they
- 324 were 95.61% and 90.82%, respectively (Fig 8).
- 325

### 326 Fig 8. Coupled forest plots showing the subgroups in the level of economic development

- 327 according to the World Bank country classification.
- 328 HIC, high-income country; LMIC, lower- and middle-income country
- 329
- 330

## 331 Level of healthcare setting

332	Four studies were done solely in tertiary-level healthcare settings, four in primary-level healthcare
333	settings, and two at both levels (which were not included in this analysis). The sensitivity and specificity
334	of AI in the real-world screening for RDR in primary-level healthcare settings were slightly higher than
335	in tertiary-level (99.35% vs 94.71%, and 93.72% vs 90.88%, respectively) (Fig 9).
336	
337	Fig 9. Coupled forest plots showing the subgroups in the level of healthcare settings.
338	
339	DR classification criteria
340	Eight studies used ICDR or its equivalence as DR classification criteria, and only two used the NHS
341	DES criteria. It is important to note that doing a subgroup in this covariate does not intend to compare
342	the two criteria but rather to see the robustness of AI in screening for RDR, even using different criteria.
343	The sensitivity and specificity of AI in the real-world screening for RDR using ICDR were 95.45% and
344	92.21%, respectively, and using NHS DES, they were 95.49% and 89.85%, respectively, which did not
345	show any significant variation (Fig 10).
346	
347	Fig 10. Coupled forest plots showing the subgroups in the DR classification criteria.
348	ICDR, International Clinical Diabetic Retinopathy; NHS DES, National Health Service Diabetic Eye
349	Screening.
350	
351	Sensitivity analysis
352	We performed sensitivity analyses on two conditions stated below. A detailed result of sensitivity
353	analyses is shown in Table 4.
354	
355	

#### 356

# Table 4. Sensitivity analyses for the accuracy of AI in detecting RDR compared with trained HGs on patient-level analysis.

Analysis	№ of Studies	№ of Participants	Sensitivity (95% CI)	Specificity (95% CI)
<b>Overall Meta-analysis</b>				
Patient-level	10	45 785	95.33% (90.60-100)	92.01% (87.61-96.42)
Sensitivity Analyses				
Only studies with DME included in the RDR definition	6	2595	95.51% (92.58-98.44)	91.35% (84.92-97.78)
Only studies with a total of $\geq$ 3 HGs	8	45 378	94.69% (90.11-99.28)	92.37% (87.93-96.81)

Data calculated using SAS® Studio.

CI, confidence interval; DME, diabetic macular edema; HG, human grader; RDR, referable diabetic retinopathy.

### 357

### 358 Inclusion of DME on the RDR definition

- 359 After excluding four studies that did not include DME as part of the RDR definition, pooled sensitivity
- 360 and specificity did not show any significant variation compared to the overall main meta-analysis

361 (95.51% vs 95.33% and 91.35% vs 92.01%, respectively) (Fig 11).

362

### **Fig 11. Coupled forest plot of studies that include DME on the RDR definition.**

- 364 DME, diabetic macular edema; RDR, referable diabetic retinopathy.
- 365

### 366 Total number of human graders

- After excluding two studies that have a total of  $\leq 2$  HGs as the ground truth, pooled sensitivity and
- 368 specificity also did not show any significant variation compared to the overall main meta-analysis
- 369 (94.69% vs 95.33% and 92.37% vs 92.01%, respectively) (Fig 12).

- Fig 12. Coupled forest plot of studies with ≥3 human graders as the ground truth on reference
- 372 standard.
- 373

### 374 Investigation of publication bias

We did not investigate publication bias since, according to Salameh, et al. [12], the statistical investigation of publication and reporting bias is not routinely recommended in systematic reviews involving DTA.

378

# 379 **Discussion**

# 380 Summary of main findings

Artificial intelligence screening incorporating a range of software applications has been evaluated for detecting referable DR in real-world settings. Studies in this review came from various economic settings and level of health care, all using recognised DR classification criteria. This review provides evidence, for the first time from prospective studies, for the effectiveness of AI in screening for RDR, in real-world settings.

This review aimed to assess the accuracy of AI solutions in detecting RDR in different resource settings. We found no variation in the diagnostic accuracy of AI, whether deployed in the LMICs or HICs, meaning AI in screening for RDR can be used universally. Regarding different DR classifications used, we found no variation between ICDR and NHS DES because both the AI models and HGs used the same criteria when grading RDR. Thus, stakeholders need to note that when integrating an AI model into a DR screening programme, the DR criteria used to train the AI model should be the same as the DR criteria used by the trained HGs in that setting or country to prevent misclassifications.

However, on the level of the healthcare setting, studies done in the primary-level healthcare settings have higher diagnostic accuracy compared to those done in tertiary-level healthcare settings. One of the reasons may be having more patients with advanced disease or other comorbidities in tertiary care settings where screening for RDR can be more challenging.

We applied the summary estimates to a hypothetical cohort of 1000 patients to our main analysis usingthe Grading of Recommendations, Assessment, Development and Evaluation (GRADE)pro guideline

development tool [33] (Table 5). Our findings suggest that if AI is used for the detection of RDR in

400	real-world settings, 95% of patients with RDR will be correctly screened positive for the condition, and
401	92% of patients with no RDR will be correctly screened negative for the condition. We were interested
402	in knowing the number of patients who will be correctly and unnecessarily referred to tertiary healthcare
403	for a further eye examination. For our prevalence rate, we used a prevalence estimate of 6.5%, which is
404	from a recent multi-ethnic study involving datasets from Singapore, the USA, China and Australia [34]
405	and a prevalence estimate of 2%, which is the national prevalence estimate of RDR in India [35]. Using
406	an RDR prevalence of 6.5%, AI will correctly detect RDR in 62 patients living with diabetes, miss
407	detecting three RDR cases while unnecessarily refer 75 patients living with diabetes without RDR, for
408	further examination.

410

### Table 5. Summary of findings of the review evaluated using the GRADEpro GDT.

**Review question:** What is the diagnostic test accuracy of AI in screening for RDR compared with trained HGs among patients with diabetes in real-world settings?

Population: People living with clinically diagnosed type 1 and type 2 diabetes

Setting: Real-world settings

Index test: Artificial intelligence

**Reference standard:** Trained HGs

Study design: Cross-sectional studies with prospective data collection

Total № of studies: 15 studies; Patient-level (Main) analysis: 10 studies (45 785 patients);

Eye-level analysis: / studies (15 390 eyes)										
Effect	Test Result	№ of results pe Tested ( Prevalence	er 1000 Samples 95% CI) Prevalence	№ of Samples (Studies)	Certainty of the Evidence (GRADE)					
()3/0 (1)		<b>2%</b> <sup>a</sup>	6.5% <sup>b</sup>	(Studies)						
Patient-level analy	sis									
Pooled sensitivity	True Positive	<b>19</b> (18-20)	<b>62</b> (59-65)	10 985 patients	$\oplus \oplus \oplus \bigcirc$					
95% (91-100%)	False Negative	1 (0-2)	<b>3</b> (0-6)	(10 studies)	MODERATE °					
Pooled specificity	True Negative	<b>902</b> (859-945)	860 (819-902)	34 890 patients	⊕⊕⊕⊖ MODERATE °					
92% (88-96%)	False Positive	78 (35-121)	75 (33-116)	(10 studies)						
Eye-level analysis										
Pooled sensitivity	True Positive	<b>18</b> (16-20)	<b>59</b> (51-65)	2913 eyes	0000					
91% (79-100%)	False Negative	2 (0-4)	<b>6</b> (0-14)	(7 studies)	<b>VERY LOW</b> d, e, f					
Pooled specificity	True Negative	<b>920</b> (888-952)	<b>878</b> (847-908)	12 477 eyes	$\oplus \oplus \oplus \odot$					
94% (91-97%)	False Positive	60 (28-92)	57 (27-88)	(7 studies)	MODERATE <sup>d</sup>					

Prevalence data calculated using GRADEpro GDT.

<sup>a</sup> National prevalence estimate of RDR in India [35]

<sup>b</sup> Prevalence estimate of RDR in a multi-ethnic study involving datasets from Singapore, the USA, Hong Kong, China and Australia [34]

<sup>c</sup> **Risk of bias (-1):** QUADAS-2 tool was used to assess for the risk of bias in the 10 studies. In the domain of *Patient Selection*, the risk of bias was high in 1 study and was unclear in 8; In the domain of *Index Test*, it was high in 4 studies and unclear in 6; In the domain of *Reference Standard*, it was high in 2 studies and unclear in 4; and in the domain of *Flow and Timing*, it was high in 1 study.

<sup>d</sup> **Risk of bias (-1)**: Risk of bias was assessed in the 7 studies of this level of analysis. In the domain of *Patient Selection*, the risk of bias was high in 2 studies and was unclear in 5; In the domain of *Index Test*, it was high in 2 studies and unclear in 4; In the domain of *Reference Standard*, it was high in 2 studies and unclear in 1; and in the domain of *Flow and Timing*, it was high in 1 study.

<sup>e</sup> **Inconsistency(-1):** Statistical heterogeneity based on the forest plot showed moderate variation in the sensitivity. <sup>f</sup> **Imprecision (-1):** The CI of the pooled sensitivity is wide, indicating that there is an uncertainty in the estimate and that the true value could potentially be lower.

#### **Grade Definition** [33]

**High:** Further research is very unlikely to change our confidence in the estimate of effect; **Moderate:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; **Low:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; **Low:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; **Very low:** Any estimate of effect is very uncertain.

AI, artificial intelligence; CI, Confidence Interval; DME, diabetic macular edema; DR, diabetic retinopathy; GDT, guideline development tool; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; HG, human grader; RDR, referable diabetic retinopathy

We also explored the effect of excluding studies that did not include DME in the RDR definition and found that the diagnostic accuracy of AI has no significant variation; this does not mean that inclusion or exclusion of DME is nonsignificant in screening for RDR, rather, this is because trained HGs adhered to the grading protocol of the study with regards to RDR definition. Furthermore, the effect of excluding studies with  $\leq 2$  trained HGs (ophthalmologists and trained and certified HGs from retina reading centres) did not affect the diagnostic accuracy of the data. This review, thus, highlights the importance of trained HGs acting as a reference standard for grading the fundus images.

420

# 421 Strengths and limitations of this review

### 422 Strengths

423 This is the first systematic review and meta-analysis assessing the diagnostic accuracy of AI in screening for RDR in real-world settings that included studies using prospective data collection. We 424 did not restrict our literature search in terms of language and publication year to minimise the chance 425 of missing studies. We were able to present the accuracy estimates in patient-level and eve-level 426 analysis, rather than just combining these data to prevent unit-of-analysis issues and avoid bias in 427 428 precision. We were able to tailor and pilot our OUADAS-2 tool to our study, adding more signalling questions to fit AI studies since QUADAS-AI by Sounderajah et al. [36] was not yet published during 429 430 the time of our review. Data extraction and assessment of the risk of bias were performed by two review authors, thus, reducing the risk of bias. We avoided all case-control studies since studies involving a 431 432 control group without RDR and patients with RDR may exaggerate the diagnosis accuracy [13]. We 433 included studies using different DR criteria (rather than just restricting to certain criteria), where results 434 showed no significant variation in the accuracy estimates.

435

436

437

### 439 **Limitations**

### 440 Eligibility

Our definition of RDR in this review is according to how the authors of the primary studies defined them, with or without DME. In the clinical setting, cases of DME should be referred for further examination when detected. However, to accurately detect DME, optical coherence tomography (OCT), which gives detailed 3D images of the eye, is the gold standard; thus, this makes fundus images less advantageous as it only provides 2D images. Therefore, it is important that further studies be done for AI models to be trained and developed to read OCT together with fundus images for higher accuracy and better applicability.

448

### 449 Quality of included studies

All eligible studies had either an unclear risk or, a high risk of bias in at least one of the QUADAS-2 domains. Amongst the included studies, 80% did not report as to how patients were enrolled in the study, making them unclear. Also, many of the studies did not clearly report a pre-specified threshold which may influence the diagnostic accuracy of the test if the authors select a positivity cut-off after obtaining the results. Thus, we support that DTA studies following the Standards for Reporting of Diagnostic Accuracy Studies (STARD) guidelines by Cohen et al. [37] or the proposed STARD-AI guidelines by Sounderajah et al. [38], when available, to avoid these uncertainties.

Regarding the QUADAS-2 domain on flow and timing, specifically as regards the signalling question 457 relating to whether all enrolled patients were included in the analysis, we deemed a study as high risk 458 459 if the discrepancies between the enrolled and analysed patients were not motivated, or were related to the severity of RDR (even though most studies have excluded ungradable images from the analysis). 460 461 This was done since including ungradable images may lead to inaccuracy and not give meaningful 462 results. Therefore, it is important that during the implementation of AI in DR screening programmes, 463 the protocol for evaluating images as ungradable should be available, (e.g. considering mydriasis, if needed, assuring quality images when capturing photos, etc.), to avoid missed detections and 464

465 unnecessary referrals since during DR screening, patients with fundus images deemed ungradable by

466 AI should also be referred to ophthalmologists for proper assessment.

467 Another limitation found is the representativity of the level of economic development by World Bank

468 country classification. The subgroup for HIC is represented only by Australia, and the subgroup LMIC,

469 only by China and India. Although there were DTA studies conducted in other countries (i.e. USA,

470 Spain, Zambia, etc), they were, unfortunately, excluded against our eligibility criteria.

471

# 472 Applicability of findings to the review question

473 Concerns regarding the applicability of all included studies were deemed low, except for two studies
474 that were not able to avoid inappropriate exclusions. We assessed the applicability of findings to our
475 review question with low concerns since all studies included AI models that were able to detect RDR
476 in real-world settings; included patients were all clinically diagnosed with type 1 and/or type 2 diabetes;
477 the grading of the same images was all compared to the grading of the trained HGs.

478

# 479 Conclusion

480 Our review provides evidence that AI could effectively screen for RDR even in real-world settings.
481 Whether in the HICs or LMICs, the detection of RDR using AI in real-world settings is highly sensitive
482 and specific. It has higher accuracy when deployed at the primary-level than in tertiary-level healthcare
483 settings.

484

# 485 **Implications for practice**

Although AI in screening for DR has been showing promising results, it is important to consider where to deploy them. Patient-wise, it will be able to screen more patients living with diabetes, leading to early diagnosis and treatment. It can also increase disease awareness, promoting a healthy lifestyle and diabetes control to these patients. However, healthcare-wise, AI might be unnecessarily referring a 490 handful of patients without RDR to tertiary healthcare centres. In HICs, where manpower is usually not 491 an issue, this might not be a problem; however, in LMICs, where it is a challenge, referring false positive 492 cases to the already few and straining eye health workers can overburden them. Thus, we recommend 493 a clinical pathway in these low-resource settings, where trained or certified lay graders in primary 494 healthcare can countercheck all the fundus images of patients who screened positive for RDR before 495 officially referring them, rather than just leaving the referral decisions to the AI system.

496

# 497 **Implications for research**

In recent years, researchers and clinicians have been advocating the use of real-world performance of AI for healthcare to evaluate further their real impact on image quality and system usability rather than just validating them using retrospective high-quality databases [24]. Our review was able to pool the diagnostic accuracy of AI in screening RDR of studies using prospective data collection; therefore, can provide recommendations to evidence-based guidelines to integrate AI in DR screening programmes in real-world settings. We recommend further studies on integrating OCT aside from using fundus imaging in AI algorithms so screening for DME will be more accurate.

505

# 506 Acknowledgements

M.E.E. is supported by a grant from the South African Medical Research Council. The views and
opinions expressed are those of the authors and do not necessarily represent the official views of the SA
MRC.

510

# 511 Author contributions

- 512 Conception of the review: Holijah Uy, Deon Minnies, Abraham Opare
- 513 Development of the protocol: Holijah Uy, Deon Minnies, Ameer Hohlfeld, Mark E Engel
- 514 Methodological advice: Mark E Engel, Ameer Hohlfeld, Eleanor Ochodo

- 515 Content advice: Mark E Engel, Christopher Fielding, Deon Minnies
- 516 Data collection: Holijah Uy, Christopher Fielding, Elton Mukonda,
- 517 Data analysis: Holijah Uy, Eleanor Ochodo, Ameer Hohlfeld, Mark E Engel
- 518 Writing of first draft: Holijah Uy
- 519 Contributions to editing subsequent versions of the protocol and manuscript:
- 520 Ameer Hohlfeld, Eleanor Ochodo, Deon Minnies, Mark E Engel
- 521

# 522 **References**

- 523 1. Teo ZL, Tham Y-C, Yan Yu MC, Chee ML, Rim TH, Cheung N, et al. Global prevalence of
- 524 diabetic retinopathy and projection of burden through 2045: Systematic review and meta-
- analysis. American Academy of Ophthalmology. 2021;128.
- 526 https://doi.org/10.1016/j.ophtha.2021.04.027
- 527 2. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Diabetic
- retinopathy preferred practice pattern. American Academy of Ophthalmology. 2019;127: P66–
- 529 P145. https://doi.org/10.1016/j.ophtha.2019.09.025
- **3.** Cuadros J. The real-world impact of artificial intelligence on diabetic retinopathy screening in
- primary care. Journal of Diabetes Science and Technology. 2021;15: 664–665.
- 532 https://doi.org/10.1177/1932296820914287
- **4.** International Council of Ophthalmology. Guidelines for diabetic eye care. San Francisco,
- 534 California: ICO; 2017. Available: <u>https://icoph.org/eye-care-delivery/diabetic-eye-care/</u>
- 535 5. Wintergerst MWM, Bejan V, Hartmann V, Schnorrenberg M, Bleckwenn M, Weckbecker K, et
- al. Telemedical diabetic retinopathy screening in a primary care setting: Quality of retinal
- 537 photographs and accuracy of automated image analysis. Ophthalmic Epidemiology. 2021;29:
- 538 286–295. <u>https://doi.org/10.1080/09286586.2021.1939886</u>
- 539

- **6.** Piyasena MMPN, Murthy GVS, Yip JLY, Gilbert C, Zuurmond M, Peto T, et al. Systematic
- 541 review on barriers and enablers for access to diabetic retinopathy screening services in different
- 542 income settings. PLoS ONE. 2019;14. <u>https://doi.org/10.1371/journal.pone.0198979</u>
- 543 7. National Institute for Clinical Excellence. Clinical Guideline E: Management of Type 2
- 544 diabetes. London: NICE; 2002.
- **8.** London School of Hygiene & Tropical Medicine. Identifying a good screening test: sensitivity,
- 546 specificity and coverage. Future Learn. Available:

547 <u>https://www.futurelearn.com/info/courses/diabetic-eye-disease/0/steps/47640</u>

- 548 9. Silpa-archa S, Limwattanayingyong J, Tadarati M, Amphornphruet A, Ruamviboonsuk P.
- 549 Capacity building in screening and treatment of diabetic retinopathy in Asia-Pacific region.
- Indian Journal of Ophthalmology. 2021;69: 2959–2967.
- 551 <u>https://doi.org/10.4103/ijo.IJO\_1075\_21</u>
- **10.** Raman R, Dasgupta D, Ramasamy K, George R, Mohan V, Ting D. Using artificial intelligence
- 553 for diabetic retinopathy screening: Policy implications. Indian Journal of Ophthalmology.
- 554 2021;69: 2993–2998. <u>https://doi.org/10.4103/ijo.IJO\_1420\_21</u>
- 555 **11.** Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering
  556 clinical impact with artificial intelligence. BMC Medicine. 2019;17.
- 557 <u>https://doi.org/10.1186/s12916-019-1426-2</u>
- 558 12. Salameh J-P, Bossuyt PM, McGrath TA, Thombs BD, Hyde CJ, Macaskill P, et al. Preferred
- reporting items for systematic review and meta-analysis of diagnostic test accuracy studies
- 560 (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020;370: m2632.
- 561 <u>https://doi.org/10.1136/bmj.m2632</u>
- **13.** Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2:
- 563 A revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal
- 564 Medicine. 2011;155: 529. <u>https://doi.org/10.7326/0003-4819-155-8-201110180-00009</u>
- 565

- 566 14. Cardoso JR, Pereira LM, Iversen MD, Ramos AL. What is gold standard and what is ground
- truth? Dental Press Journal of Orthodontics. 2014;19: 27–30. <u>https://doi.org/10.1590/2176-</u>
  9451.19.5.027-030.ebo
- 569 15. Dong X, Du S, Zheng W, Cai C, Liu H, Zou J. Evaluation of an artificial intelligence system for
- 570 the detection of diabetic retinopathy in Chinese community healthcare centers. Frontiers in
- 571 Medicine. 2022;9. https://doi.org/10.3389/fmed.2022.883462
- 572 16. Gulshan V, Rajan RP, Widner K, Wu D, Wubbels P, Rhodes T, et al. Performance of a deep-
- 573 learning algorithm vs manual grading for detecting diabetic retinopathy in India. JAMA
- 574 Ophthalmology. 2019;137: 987. https://doi.org/10.1001/jamaophthalmol.2019.2004
- 575 17. Hao S, Liu C, Li N, Wu Y, Li D, Gao Q, et al. Clinical evaluation of AI-assisted screening for
- 576 diabetic retinopathy in rural areas of Midwest China. Grzybowski A, editor. PLOS ONE.
- 577 2022;17: e0275983. <u>https://doi.org/10.1371/journal.pone.0275983</u>
- **18.** He J, Cao T, Xu F, Wang S, Tao H, Wu T, et al. Artificial intelligence-based screening for

diabetic retinopathy at community hospital. Eye. 2019;34: 572–576.

580 https://doi.org/10.1038/s41433-019-0562-4

- 581 19. Jain A, Krishnan R, Rogye A, Natarajan S. Use of offline artificial intelligence in a smartphone-
- based fundus camera for community screening of diabetic retinopathy. Indian Journal of
- 583 Ophthalmology. 2021;69: 3150. <u>https://doi.org/10.4103/ijo.ijo\_3808\_20</u>
- **20.** Kanagasingam Y, Xiao D, Vignarajan J, Preetham A, Tay-Kearney M-L, Mehrotra A.
- 585 Evaluation of artificial intelligence-based grading of diabetic retinopathy in primary care.
- 586 JAMA Network Open. 2018;1: e182665. <u>https://doi.org/10.1001/jamanetworkopen.2018.2665</u>
- 587 21. Keel S, Lee PY, Scheetz J, Li Z, Kotowicz MA, MacIsaac RJ, et al. Feasibility and patient
- 588 acceptability of a novel artificial intelligence-based screening model for diabetic retinopathy at
- endocrinology outpatient services: A pilot study. Scientific Reports. 2018;8.
- 590 https://doi.org/10.1038/s41598-018-22612-2

- 592 22. Li N, Ma M, Lai M, Gu L, Kang M, Wang Z, et al. A stratified analysis of a deep learning
- algorithm in the diagnosis of diabetic retinopathy in a real-world study. Journal of Diabetes.

594 2021;14: 111–120. <u>https://doi.org/10.1111/1753-0407.13241</u>

- 595 23. Natarajan S, Jain A, Krishnan R, Rogye A, Sivaprasad S. Diagnostic accuracy of community-
- based diabetic retinopathy screening with an offline artificial intelligence system on a
- smartphone. JAMA Ophthalmology. 2019;137: 1182.
- 598 https://doi.org/10.1001/jamaophthalmol.2019.2923
- 599 24. Rajalakshmi R, Subashini R, Anjana RM, Mohan V. Automated diabetic retinopathy detection
- in smartphone-based fundus photography using artificial intelligence. Eye. 2018;32: 1138–
- 601 1144. <u>https://doi.org/10.1038/s41433-018-0064-9</u>
- 602 25. Scheetz J, Koca D, McGuinness M, Holloway E, Tan Z, Zhu Z, et al. Real-world artificial
- 603 intelligence-based opportunistic screening for diabetic retinopathy in endocrinology and
- indigenous healthcare settings in Australia. Scientific Reports. 2021;11.
- 605 <u>https://doi.org/10.1038/s41598-021-94178-5</u>
- 606 26. Sosale B, Aravind SR, Murthy H, Narayana S, Sharma U, Gowda SGV, et al. Simple, mobile-
- based artificial intelligence algorithm in the detection of diabetic retinopathy (SMART) study.
- BMJ Open Diabetes Research & Care. 2020;8: e000892. <u>https://doi.org/10.1136/bmjdrc-2019-</u>
  000892
- **27.** Yang Y, Pan J, Yuan M, Lai K, Xie H, Ma L, et al. Performance of the AIDRScreening system
- 611 in detecting diabetic retinopathy in the fundus photographs of Chinese patients: A prospective,
- multicenter, clinical study. Annals of Translational Medicine. 2022;10: 1088–1088.
- 613 <u>https://doi.org/10.21037/atm-22-350</u>
- 614 28. Zhang Y, Shi J, Peng Y, Zhao Z, Zheng Q, Wang Z, et al. Artificial intelligence-enabled
- screening for diabetic retinopathy: A real-world, multicenter and prospective study. BMJ Open
- 616 Diabetes Research & Care. 2020;8: e001596. <u>https://doi.org/10.1136/bmjdrc-2020-001596</u>

- 618 **29.** Zhang W, Li D, Wei Q, Ding D, Meng L, Wang Y, et al. The validation of deep learning-based
- 619 grading model for diabetic retinopathy. Frontiers in Medicine. 2022;9.
- 620 https://doi.org/10.3389/fmed.2022.839088
- 621 **30.** Hong Kong Baptist University, Department of Mathematics. Mean variance estimation. In:
- 622 www.math.hkbu.edu.hk [Internet]. 2023 [cited 8 Apr 2023]. Available:
- 623 <u>https://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html</u>
- **31.** Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test
- accuracy evaluations. Statistics in Medicine. 2001;20: 2865–2884.
- 626 <u>https://doi.org/10.1002/sim.942</u>
- 627 32. Hamaddeh N, Van Rompaey C, Metreau E, Eapen SG. New World Bank country classifications
- by income level: 2022-2023. In: World Bank Blogs [Internet]. World Bank Group; 1 Jul 2022.
- 629 Available: <u>https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-</u>
- 630 <u>income-level-2022-2023</u>
- 33. McMaster University, Evidence Prime. GRADEpro GDT: GRADEpro guideline development
   tool [Software]. 2022. Available: gradepro.org
- **34.** Ting DSW, Cheung CY, Nguyen Q, Sabanayagam C, Lim G, Lim ZW, et al. Deep learning in
- estimating prevalence and systemic risk factors for diabetic retinopathy: A multi-ethnic study.
- 635 Nature Partner Journals: Digital Medicine. 2019;2. <u>https://doi.org/10.1038/s41746-019-0097-x</u>
- 636 **35.** Sheikh A, Bhatti A, Adeyemi O, Raja M, Sheikh I. The utility of smartphone-based artificial
- 637 intelligence approaches for diabetic retinopathy: A literature review and meta-analysis. Journal
- 638 of Current Ophthalmology. 2021;33: 219. <u>https://doi.org/10.4103/2452-2325.329064</u>
- 639 **36.** Sounderajah V, Ashrafian H, Rose S, Shah NH, Ghassemi M, Golub R, et al. A quality
- 640 assessment tool for artificial intelligence-centered diagnostic test accuracy studies: QUADAS-
- 641 AI. Nature Medicine. 2021;27: 1663–1665. <u>https://doi.org/10.1038/s41591-021-01517-0</u>
- 642
- 643 37. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015
- 644 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open.
- 645 2016;6: e012799. <u>https://doi.org/10.1136/bmjopen-2016-012799</u>

- 646 **38.** Sounderajah V, Ashrafian H, Golub RM, Shetty S, De Fauw J, Hooft L, et al. Developing a
- 647 reporting guideline for artificial intelligence-centred diagnostic test accuracy studies: the
- 648 STARD-AI protocol. BMJ Open. 2021;11: e047709. <u>https://doi.org/10.1136/bmjopen-2020-</u>
- 649 <u>047709</u>
- 650

# 651 Supporting Information

- 652 S1 Table. Search strategy
- 653 S2 Table. PRISMA-DTA









Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
He 2020	91	12	10	776	0.90 [0.83, 0.95]	0.98 [0.97, 0.99]	-	
Jain 2021	68	136	0	1166	1.00 [0.95, 1.00]	0.90 [0.88, 0.91]		
Kanagasingam 2018	2	15	0	176	1.00 [0.16, 1.00]	0.92 [0.87, 0.96]		-
Keel 2018	12	5	1	75	0.92 [0.64, 1.00]	0.94 [0.86, 0.98]		-
Natarajan 2019	15	23	0	176	1.00 [0.78, 1.00]	0.88 [0.83, 0.93]		-
Rajalakshmi 2018	141	48	1	106	0.99 [0.96, 1.00]	0.69 [0.61, 0.76]		
Scheetz 2021	31	21	1	150	0.97 [0.84, 1.00]	0.88 [0.82, 0.92]		
Sosale 2020	187	52	14	647	0.93 [0.89, 0.96]	0.93 [0.90, 0.94]		
Yang 2022	346	22	53	541	0.87 [0.83, 0.90]	0.96 [0.94, 0.98]		
Zhang 2020	8265	2306	1657	28437	0.83 [0.83, 0.84]	0.92 [0.92, 0.93]		



Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Dong 2022	184	46	49	569	0.79 [0.73, 0.84]	0.93 [0.90, 0.94]	-	
Gulshan 2019	569	99	71	1166	0.89 [0.86, 0.91]	0.92 [0.91, 0.94]		
Hao 2022	630	111	507	5606	0.55 [0.52, 0.58]	0.98 [0.98, 0.98]		
Jain 2021	107	205	0	2314	1.00 [0.97, 1.00]	0.92 [0.91, 0.93]		
Li 2021	126	67	22	1459	0.85 [0.78, 0.90]	0.96 [0.94, 0.97]	-	
Natarajan 2019	23	46	0	325	1.00 [0.85, 1.00]	0.88 [0.84, 0.91]		
Zhang 2022	581	31	44	433	0.93 [0.91, 0.95]	0.93 [0.91, 0.95]	0 0.2 0.4 0.6 0.8 1	



# LMIC

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
He 2020	91	12	10	776	0.90 [0.83, 0.95]	0.98 [0.97, 0.99]	-	
Jain 2021	68	136	0	1166	1.00 [0.95, 1.00]	0.90 [0.88, 0.91]	-	
Natarajan 2019	15	23	0	176	1.00 [0.78, 1.00]	0.88 [0.83, 0.93]		
Rajalakshmi 2018	141	48	1	106	0.99 [0.96, 1.00]	0.69 [0.61, 0.76]	-	-
Sosale 2020	187	52	14	647	0.93 [0.89, 0.96]	0.93 [0.90, 0.94]	-	
Yang 2022	346	22	53	541	0.87 [0.83, 0.90]	0.96 [0.94, 0.98]	-	
Zhang 2020	8265	2306	1657	28437	0.83 [0.83, 0.84]	0.92 [0.92, 0.93]		
							0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

# HIC

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
Kanagasingam 2018	2	15	0	176	1.00 [0.16, 1.00]	0.92 [0.87, 0.96]
Keel 2018	12	5	1	75	0.92 [0.64, 1.00]	0.94 [0.86, 0.98]
Scheetz 2021	31	21	1	150	0.97 [0.84, 1.00]	0.88 [0.82, 0.92]



# **Primary Level**

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)
He 2020	91	12	10	776	0.90 [0.83, 0.95]	0.98 [0.97, 0.99]
Jain 2021	68	136	0	1166	1.00 [0.95, 1.00]	0.90 [0.88, 0.91]
Kanagasingam 2018	2	15	0	176	1.00 [0.16, 1.00]	0.92 [0.87, 0.96]
Natarajan 2019	15	23	0	176	1.00 [0.78, 1.00]	0.88 [0.83, 0.93]



# **Tertiary Level**

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	
Keel 2018	12	5	1	75	0.92 [0.64, 1.00]	0.94 [0.86, 0.98]	
Rajalakshmi 2018	141	48	1	106	0.99 [0.96, 1.00]	0.69 [0.61, 0.76]	
Sosale 2020	187	52	14	647	0.93 [0.89, 0.96]	0.93 [0.90, 0.94]	
Yang 2022	346	22	53	541	0.87 [0.83, 0.90]	0.96 [0.94, 0.98]	



# ICDR

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
He 2020	91	12	10	776	0.90 [0.83, 0.95]	0.98 [0.97, 0.99]	-	
Jain 2021	68	136	0	1166	1.00 [0.95, 1.00]	0.90 [0.88, 0.91]	-	
Kanagasingam 2018	2	15	0	176	1.00 [0.16, 1.00]	0.92 [0.87, 0.96]		-
Natarajan 2019	15	23	0	176	1.00 [0.78, 1.00]	0.88 [0.83, 0.93]		
Rajalakshmi 2018	141	48	1	106	0.99 [0.96, 1.00]	0.69 [0.61, 0.76]		-
Sosale 2020	187	52	14	647	0.93 [0.89, 0.96]	0.93 [0.90, 0.94]		
Yang 2022	346	22	53	541	0.87 [0.83, 0.90]	0.96 [0.94, 0.98]		
Zhang 2020	8265	2306	1657	28437	0.83 [0.83, 0.84]	0.92 [0.92, 0.93]	0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1
NHS DES								
Study	ТР	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Keel 2018	12	5	1	75	0.92 [0.64, 1.00]	0.94 [0.86, 0.98]		-
Scheetz 2021	31	21	1	150	0.97 [0.84, 1.00]	0.88 [0.82, 0.92]	0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

# DME Included

Study	TP	FP	FN	ΤN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
He 2020	91	12	10	776	0.90 [0.83, 0.95]	0.98 [0.97, 0.99]	-	
Keel 2018	12	5	1	75	0.92 [0.64, 1.00]	0.94 [0.86, 0.98]		-
Natarajan 2019	15	23	0	176	1.00 [0.78, 1.00]	0.88 [0.83, 0.93]		
Rajalakshmi 2018	141	48	1	106	0.99 [0.96, 1.00]	0.69 [0.61, 0.76]		-
Scheetz 2021	31	21	1	150	0.97 [0.84, 1.00]	0.88 [0.82, 0.92]		-
Sosale 2020	187	52	14	647	0.93 [0.89, 0.96]	0.93 [0.90, 0.94]		



# Human Graders ≥ 3

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
He 2020	91	12	10	776	0.90 [0.83, 0.95]	0.98 [0.97, 0.99]	-	
Jain 2021	68	136	0	1166	1.00 [0.95, 1.00]	0.90 [0.88, 0.91]	-	•
Keel 2018	12	5	1	75	0.92 [0.64, 1.00]	0.94 [0.86, 0.98]		-
Rajalakshmi 2018	141	48	1	106	0.99 [0.96, 1.00]	0.69 [0.61, 0.76]		
Scheetz 2021	31	21	1	150	0.97 [0.84, 1.00]	0.88 [0.82, 0.92]	-	
Sosale 2020	187	52	14	647	0.93 [0.89, 0.96]	0.93 [0.90, 0.94]		
Yang 2022	346	22	53	541	0.87 [0.83, 0.90]	0.96 [0.94, 0.98]		
Zhang 2020	8265	2306	1657	28437	0.83 [0.83, 0.84]	0.92 [0.92, 0.93]		
							0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1